As a research-led healthcare company, we strive to develop medicines where there is high unmet clinical need.
Wintermute has multiple therapeutic compounds in its development pipeline. Wintermute compounds demonstrate exceptional potential for the treatment of infections. Some key advantages of include:
High levels of potency, providing rapid eradication of infectious organisms.
High levels of safety captured during in-vitro and in-vivo testing.
Activity against gram-positive and gram-negative bacteria, fungi and viruses.
Zero evidence of resistance development during standardized testing.
Ongoing protection against infections.
With no harmful chemicals and water-based.
Wintermute compounds have demonstrated efficacy for a wide range of organisms; most of which make up the CDC’s Biggest Threats list
Wintermute compounds are currently being developed for treating skin infections and wounds, including those caused by Methicillin-resistant Staphylococcus aureus MRSA and other drug-resistant bacteria. Skin infections are among the most common diseases worldwide, placing an immense burden on global healthcare. In 2010, skin infection ranked 4th among all diseases for years lost due to disability (YLD). It is estimated that up to 70% of all people will suffer one or more skin diseases during their lifetime. The micro-organism responsible for the majority of skin infections is Staphylococcus aureus, of which over 60% are MRSA strains (known as “golden staph”).
At Wintermute Biomedical, we are performing leading-edge research and development into the discovery of next-generation therapeutics and consumer products to prevent and combat infectious diseases. In addition to progressing Wintermute compounds for treating skin infections, we are actively researching, developing and testing:
Antibacterials, anti-virals and anti-fungals.
Systemic therapeutics, including for the treatment of respiratory disease and blood stream infections.
Medical device coatings for infection control.
Wintermute compounds are in pre-clinical development, and are anticipated to enter clinical trials soon.
Our team won’t rest until Wintermute compounds are available to the many patients who desperately need it.
